Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients

被引:52
|
作者
Emerling, Brooke M. [1 ,2 ]
Benes, Cyril H. [3 ,4 ]
Poulogiannis, George [1 ,2 ]
Bell, Eric L. [5 ]
Courtney, Kevin [6 ,7 ]
Liu, Hui [1 ,2 ]
Choo-Wing, Rayman [1 ,2 ]
Bellinger, Gary [1 ,2 ]
Tsukazawa, Kazumi S. [1 ,2 ]
Brown, Victoria [6 ,8 ]
Signoretti, Sabina [6 ,8 ]
Soltoff, Stephen P. [2 ]
Cantley, Lewis C. [1 ,2 ]
机构
[1] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA
[2] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA
[4] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[5] MIT, Dept Biol, Paul F Glenn Lab, Cambridge, MA 02139 USA
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[7] Univ Texas SW Med Ctr Dallas, Div Hematol Oncol, Dallas, TX 75390 USA
[8] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
kidney cancer; oxygen deprivation; DOMAIN-CONTAINING PROTEIN-1; CUB-DOMAIN; HIF-ALPHA; PKC-DELTA; VHL LOSS; SRC; INHIBITION; SUBSTRATE; SUPPRESSION; EXPRESSION;
D O I
10.1073/pnas.1222435110
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CUB domain-containing protein 1 (CDCP1) is a transmembrane protein that is highly expressed in stem cells and frequently overexpressed,and tyrosine-phosphorylated in cancer. CDCP1 promotes cancer cell metastasis. However, the mechanisms that regulate CDCP1 are not well-defined. Here we show that hypoxia induces CDCP1 expression and tyrosine phosphorylation in hypoxia-inducible factor (HIF)-2 alpha-, but not HIF-l alpha-, dependent fashion. shRNA knockdown of CDCP1 impairs cancer cell migration under hypoxic conditions, whereas overexpression of HIF-2 alpha promotes the growth of tumor xenografts in association with enhanced CDCP1 expression and tyrosine phosphorylation. Immunohistochemistry analysis of tissue microarray samples from tumors of patients with clear cell renal cell carcinoma shows that increased CDCP1 expression correlates with decreased overall survival. Together, these data support a critical role for CDCP1 as a unique HIF-2 alpha target gene involved in the regulation of cancer metastasis, and suggest that CDCP1 is a biomarker and potential therapeutic target for metastatic cancers.
引用
收藏
页码:3483 / 3488
页数:6
相关论文
共 50 条
  • [1] Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients (vol 110, pg 3483, 2013)
    Emerling, Brooke M.
    Benes, Cyril H.
    Poulogiannis, George
    Bell, Eric L.
    Courtney, Kevin
    Liu, Hui
    Choo-Wing, Rayman
    Bellinger, Gary
    Tsukazawa, Kazumi S.
    Brown, Victoria
    Signoretti, Sabina
    Soltoff, Stephen P.
    Cantley, Lewis C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (32)
  • [2] Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma.
    Doshi, Sahil D.
    Kuo, Fengshen
    Knezevic, Andrea
    Kotecha, Ritesh R.
    Motzer, Robert J.
    Hakimi, A. Ari
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 445 - 445
  • [3] Identification of CDCP1 as a HIF-2α target gene involved in the regulation of cancer cell migration and metastasis
    Emerling, Brooke M.
    Benes, Cyril
    Bell, Eric
    Poulogiannis, George
    Courtney, Kevin
    Lui, Hui
    Choo-Wing, Rayman
    Bellinger, Gary
    Soltoff, Stephen
    Cantley, Lewis
    CANCER RESEARCH, 2013, 73 (08)
  • [4] Hypoxia-inducible factor 1α in clear cell renal cell carcinoma
    Klatte, Tobias
    Seligson, David B.
    Riggs, Stephen B.
    Leppert, John T.
    Berkman, Maria K.
    Kleid, Mark D.
    Yu, Hong
    Kabbinavar, Fairooz F.
    Pantuck, Allan J.
    Belldegrun, Arie S.
    CLINICAL CANCER RESEARCH, 2007, 13 (24) : 7388 - 7393
  • [5] Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma
    Raval, RR
    Lau, KW
    Tran, MGB
    Sowter, HM
    Mandriota, SJ
    Li, JL
    Pugh, CW
    Maxwell, PH
    Harris, AL
    Ratcliffe, PJ
    MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (13) : 5675 - 5686
  • [6] HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY GENES PREDICT OVERALL SURVIVAL FOR METASTATIC CLEAR CELL RENAL CELL CARCINOMA
    Kuhlmann, Paige K.
    Su, Shengchen
    You, Sungyong
    Patel, Devin
    Rini, Brian
    Halabi, Susan
    Small, Eric J.
    Kim, Hyung L.
    JOURNAL OF UROLOGY, 2020, 203 : E808 - E809
  • [7] Primary endothelial cell-specific regulation of hypoxia-inducible factor (HIF)-1 and HIF-2 and their target gene expression profiles during hypoxia
    Bartoszewski, Rafal
    Moszynska, Adrianna
    Serocki, Marcin
    Cabaj, Aleksandra
    Polten, Andreas
    Ochocka, Renata
    Dell'Italia, Louis
    Bartoszewska, Sylwia
    Kroliczewski, Jaroslaw
    Dabrowski, Michal D.
    Collawn, James F.
    FASEB JOURNAL, 2019, 33 (07): : 7929 - 7941
  • [8] Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma
    Choi, Won Seok W.
    Boland, Julia
    Lin, Jianqing
    JOURNAL OF KIDNEY CANCER AND VHL, 2021, 8 (02): : 1 - 7
  • [9] Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Tykodi, Scott S.
    Bauer, Todd Michael
    McDermott, David F.
    Arrowsmith, Edward
    Zojwalla, Naseem J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma
    Tamukong, Patrick K.
    Kuhlmann, Paige
    You, Sungyong
    Su, Shengchen
    Wang, Yanping
    Yoon, Samantha
    Gong, Jun
    Figlin, Robert A.
    Janes, Jessica L.
    Freedland, Stephen J.
    Halabi, Susan
    Small, Eric J.
    Rini, Brian I.
    Kim, Hyung L.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (11) : 495.e1 - 495.e10